A New York City biotech company is openly making the case that the world should rethink its near-universal prohibition on creating genetically modified human babies, arguing that the benefits of its technology may now outweigh the risks that led to a global ban.
Origin Genomics, a startup founded and led by CEO Cathy Tie, has set its mission on proving that editing disease-causing genes in human embryos can be done responsibly, according to an exclusive tour and interview granted to NPR. The company's work sits at the center of one of the most fraught ethical debates in modern science: whether it is acceptable to alter the genetic makeup of children before they are born.
Tie, wearing a white lab coat bearing her name alongside the company's logo, guided an NPR reporter, photographer and videographer through the startup's laboratories, which are located somewhere in New York City. The exact address was withheld at Tie's request for security reasons — a reflection of how contentious the field remains.
The story of Origin Genomics begins with embryos. During the tour, Tie stepped into the lab, pulled on blue rubber gloves and pointed to a gray metal tank on the floor that resembled an oversized thermos. Inside, she explained, was liquid nitrogen: the cryogenic storage system preserving the human embryos at the heart of the company's research.
Tie twisted open the tank's black lid, releasing curls of white vapor from the super-cold liquid inside. From the tank she carefully withdrew a long metal rod, its end cradling frosted glass tubes holding the frozen specimens. Four tubes were visible, she noted, and each one can hold as many as ten embryos.
Those embryos were not created for research alone. According to the company, they were donated by couples whose families have struggled for generations with life-threatening inherited disorders — conditions that can be passed from parent to child and that sometimes strike multiple relatives across a family tree. One married couple who contributed embryos later spoke with NPR about their hope of one day having healthy children with the help of gene editing.
The science Origin Genomics is pursuing centers on extracting stem cells from donated embryos, then using those cells to test the company's technology for repairing defective genes. The goal is to demonstrate that faulty DNA responsible for serious disease can be corrected at the embryonic stage, before a pregnancy is established.
But carrying that work through to an actual pregnancy would place the company in direct conflict with the law. Creating gene-edited babies is currently illegal, a prohibition that traces back to international outrage over a Chinese scientist who shocked the world in 2018 by producing the first gene-edited infants. That case, widely condemned as reckless and unethical, hardened the global consensus against heritable human genome editing.
Origin Genomics is not claiming that the existing ban is scientifically unnecessary. Instead, the startup is arguing that its research may show the calculus has changed — that the possibility of sparing children from devastating genetic diseases could justify revisiting rules long treated as settled. The company frames its mission explicitly as proving that the potential benefits of editing disease-causing genes in human embryos now outweigh the risks.
That claim runs straight into a thicket of objections. Critics of heritable gene editing warn about unintended consequences that could ripple through future generations, since changes made to an embryo's DNA would be passed down to its descendants. They also raise concerns about safety, consent — the unborn child cannot agree to be modified — and the prospect of a slippery slope toward designer babies engineered for traits like height or intelligence rather than medical need.
The embryos stored in Origin Genomics' cryogenic tank represent families with a concrete stake in the outcome. For couples who carry genes for severe disorders, the alternatives are limited: they may face difficult choices about whether to conceive at all, undergo prenatal testing, or select embryos through in vitro fertilization. Gene editing, if it proved safe and legal, could offer another path.
For now, the company's tests remain confined to cells in the lab. But Tie's decision to invite journalists behind the scenes signals a broader strategic push: bringing heritable gene editing out of the shadows and into public conversation, at a moment when the technology is advancing faster than the laws governing it.
The debate Origin Genomics wants to reopen is not merely technical. It touches on questions of regulation, reproductive freedom, disability rights and the meaning of parenthood. Supporters of a reexamination argue that a blanket ban may eventually drive the work underground or overseas, while opponents counter that legalizing it would legitimize an experiment whose consequences cannot be undone.
What happens next depends on whether regulators and the public are willing to reconsider a line drawn after one infamous case — and whether a startup with a tank of frozen embryos can convince the world that the risks are worth taking.
(0)